← All trials
NCT05397041
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 6, 2022
- Primary completion
- May 28, 2023
- Completion date
- May 28, 2023
- First posted
- May 31, 2022
- Last posted
- Sep 21, 2022
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bright Minds BiosciencesLead sponsor
- CMAX Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.